June 13, 2024

Brucellosis Vaccines Market Size to Reach USD 389.50 Mn by 2033

The global brucellosis vaccines market size reached USD 242.70 million in 2023 and is projected to attain around USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.

Key Points

  • The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
  • North America has dominated the market with revenue share of 43% in 2023.
  • By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
  • By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
  • By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
  • By distribution channel, the public segment had the largest market share in 2023.

Brucellosis Vaccines Market Size 2024 to 2033

Brucellosis is a zoonotic disease that can spread from animals to humans, typically caused by bacteria of the Brucella genus. Vaccines play a crucial role in controlling and preventing the spread of brucellosis in both humans and animals. The brucellosis vaccines market encompasses the development, production, and distribution of vaccines for animals and potentially humans. Current vaccines primarily target livestock, such as cattle, pigs, and sheep, to curb the spread of the disease.

Get a Sample: https://www.precedenceresearch.com/sample/4113

Growth Factors:

The growth of the brucellosis vaccines market is primarily driven by the increasing prevalence of brucellosis in different regions, leading to heightened demand for effective vaccines. The rising awareness of zoonotic diseases and their impact on human health and the agricultural economy is also fueling market growth. Additionally, government initiatives and policies aimed at controlling animal diseases and enhancing food safety contribute to market expansion.

Region Insights:

Different regions are affected by brucellosis to varying degrees. For instance, regions with a high concentration of livestock, such as parts of Asia, Africa, and Latin America, may experience higher demand for brucellosis vaccines. Meanwhile, developed regions like North America and Europe have established control measures, but there may still be niche markets for vaccines targeting specific livestock populations.

Brucellosis Vaccines Market Scope

Report Coverage Details
Global Market Size in 2023 USD 242.70 Million
Global Market Size in 2024 USD 254.46 Million
Global Market Size by 2033 USD 389.50 Million
Growth Rate from 2024 to 2033 CAGR of 4.84%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type, By Vaccine, By Application, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Brucellosis Vaccines Market Dynamics


Key drivers of the brucellosis vaccines market include the need for improved animal health and productivity, economic losses from infected livestock, and the impact of zoonotic diseases on human populations. The push for higher agricultural output and the desire to minimize losses due to disease also fuel demand for effective vaccines.


Opportunities in the brucellosis vaccines market include advancements in vaccine technology, such as DNA-based or subunit vaccines, which may offer better efficacy and safety profiles. Additionally, there is potential for growth in emerging markets as awareness of brucellosis and the benefits of vaccination increase.


The brucellosis vaccines market faces challenges such as regulatory hurdles, as developing and marketing vaccines for both human and animal use requires extensive testing and approval processes. Another challenge is vaccine efficacy and safety, as brucellosis vaccines must be both safe and effective across different animal species. Additionally, the varying strains of Brucella in different regions may complicate vaccine development and distribution.

Read Also: Dental Caries Treatment Market Size to Reach USD 11.60 Bn by 2033

Brucellosis Vaccines Market Recent Developments

  • In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
  • In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
  • In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
  • In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.

Brucellosis Vaccines Market Companies

  • Merck & Co.
  • CZ Vaccines
  • Colorado Serum Company
  • Indian Immunologicals
  • Hester Biosciences
  • Veterinary Technologies Corporation
  • Laboratorios Tornel
  • Five Animal Health
  • VETAL Animal Health Products Inc.

Segments Covered in the Report

By Type

  • Rbs1 Vaccine
  • S19 Vaccine
  • Others

By Vaccine

  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine

By Application

  • Cattle
  • Sheep & Goat
  • Others

By Distribution Channel

  • Veterinary Hospitals & Clinics
  • Retail Channels
  • Public

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Leave a Reply

Your email address will not be published. Required fields are marked *